# A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer

> **NCT07301229** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 100 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (PDAC)

## Interventions

- **DRUG:** HLX43 DOSE 1 (2.5 mg/kg)
- **DRUG:** HLX43 DOSE 2 (3.0 mg/kg)

## Key facts

- **NCT ID:** NCT07301229
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-29
- **Primary completion:** 2028-02-21
- **Final completion:** 2028-03-23
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07301229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07301229, "A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07301229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*